Comments
Pharma major Dr Reddy's Laboratories Ltd has filed an appeal in the district court of Texas in a patent infringement case with Pozen Inc on the generic version of Trexime (sumatriptan/naproxen sodium).
This was informed by Pozen to the US Securities Exchange Commission (SEC) in a filing.
In a ruling last month, the US court upheld the validity of Pozen's patent on Treximet formulation. It also said the abbreviated new drug applications (ANDA) filed by the Hyderabad-based company and Par Pharmaceutical, Inc infringed Pozen's patent.
The US Food and Drug Administration was also asked not to approve the ANDAs till the expiration of the Pozen's patent in 2025.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.